CACNG1: A Promising Gene for Neurodegenerative Diseases (G786)

Target Name: CACNG1

NCBI ID: G786

CACNG1

Other Name(s): CCG1_HUMAN | CACNLG | calcium channel, voltage-dependent, gamma subunit 1 | dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma | L-type calcium channel gamma polypeptide | Calcium voltage-gated channel auxiliary subunit gamma 1 | calcium voltage-gated channel auxiliary subunit gamma 1 | Dihydropyridine-sensitive L-type, skeletal muscle calcium channel subunit gamma | Neuronal dihydropyridine-sensitive calcium channel gamma subunit | neuronal dihydropyridine-sensitive calcium channel gamma subunit | Voltage-dependent calcium channel gamma-1 subunit

CACNG1: A Promising Gene for Neurodegenerative Diseases

CACNG1 (CCG1_HUMAN) is a gene that encodes a protein known as CACNG1. CACNG1 is a member of the CCR4-like superfamily and is located on chromosome 6p21.2. It is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell signaling, neurodegeneration, and cancer.

One of the most promising aspects of CACNG1 is its potential as a drug target. Researchers have identified several potential drug targets for CACNG1, including those associated with neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Huntington's disease.

One of the primary drug targets for CACNG1 is the neurotransmitter dopamine. CACNG1 has been shown to regulate the levels of dopamine in the brain and has been linked to the development of neurodegenerative diseases. By targeting CACNG1, researchers hope to reduce the levels of dopamine in the brain and potentially slow the progression of neurodegenerative diseases.

Another potential drug target for CACNG1 is the protein synaptophysin. Synaptophysin is a protein that helps maintain the structure and function of the synapse, the chemical bridge between neurons. Researchers have shown that CACNG1 plays a role in the regulation of synaptophysin levels and that alterations in synaptophysin levels may contribute to neurodegenerative diseases.

CACNG1 has also been shown to be involved in the regulation of cellular signaling pathways that are important for brain development and function. For example, CACNG1 has been shown to be involved in the regulation of the Wnt signaling pathway, a pathway that is important for the development and maintenance of neural stem cells.

In addition to its potential drug targets, CACNG1 also has potential as a biomarker for various neurodegenerative diseases. For example, CACNG1 has been shown to be decreased in the brains of individuals with Alzheimer's disease, and levels of CACNG1 have been associated with an increased risk of developing Parkinson's disease.

Overall, CACNG1 is a promising gene as a drug target and biomarker for various neurodegenerative diseases. Further research is needed to fully understand the role of CACNG1 in neural development and function, as well as its potential as a drug and biomarker.

Protein Name: Calcium Voltage-gated Channel Auxiliary Subunit Gamma 1

Functions: Regulatory subunit of the voltage-gated calcium channel that gives rise to L-type calcium currents in skeletal muscle. Regulates channel inactivation kinetics

The "CACNG1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNG1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets